4dmedical Ltd. · ASX:4DX
4dmedical — Shareholder Meeting (October 2026)
40 slides from 4dmedical's shareholder meeting presentation, Oct 28, 2026
Slide 1: Presentation and Chair's address to the 2026 AGM
ASX announcement ASX:4DX Presentation and Chair’s address to the 2026 Annual General Meeting 28 October 2026 For personal use only Melbourne, Australia, 28 October 2026: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) attaches the following materials to be presented at the Annual General
Slide 2: Chair's address: Dear Shareholders
Dear Shareholders, Welcome to 4DMedical’s 2026 AGM. I am pleased to present our Annual Report for financial year 2026 and reflect on a year that has been both significant and transformational for our Company. Over the past twelve months, we have continued to strengthen our position as a growing leader
Slide 3: Closing Remarks
Closing Remarks I am very proud of our extraordinary global team and their commitment to 4DMedical’s mission to improve global health outcomes. I have every confidence that the team has the capability to advance its mission and commercial growth. For personal use only I will continue to closely watch
Slide 4: Annual General Meeting October 2026
4DMedical Limited (ASX:4DX) Annual General Meeting 28 October 2026 Delivering Next- rsonal use only Generation Cardiopulmonary Imaging to the World Copyright © 4DMedical Limited 2026 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia ABN 31 161 684 831 www.4dmedical.co
Slide 5: Disclaimer
Disclaimer rsonal use only This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and their activities current as of 28 October 2026 unless otherwise stated and the informat
Slide 6: Agenda
Agenda rsonal use only 1. Opening & introductions 2. Chair’s address 3. CEO’s address 4. Procedural matters 5. Formal business & poll 6. Q&A & close of meeting 3 4DMedical Limited (ASX:4DX) October 2026
Slide 7: Board of Directors
Board of Directors – significant medical and commercial sector experience rsonal use only Lil Bianchi Julian Sutton Dr Andreas Fouras PhD Non-Executive Chair (Outgoing) & Executive Director & CFO (Incoming Chair) Managing Director and CEO Chair of the Audit and Risk Committee Experienced executive w
Slide 8: Chair's address
Chair’s address Lil Bianchi rsonal use only Non-Executive Chair (Outgoing) 5
Slide 9: CEO's address
CEO’s address Dr Andreas Fouras PhD rsonal use only Managing Director & CEO 6
Slide 10: 4DMedical: An overview
4DMedical: An overview 4DMedical is a global medical technology company, changing the outcome for patients with lung disease rsonal use only by revolutionising respiratory imaging through ventilation and perfusion analysis CT:VQ® - the world’s first and only non-contrast lung The leading pulmonary
Slide 11: FY26: Foundations for rapid growth
FY26: Foundations for rapid growth Regulatory access, clinical evidence, reimbursement and geographic footprint in place. 6 CT:VQ® 39% 77% 21% $278m rsonal use only markets SaaS sites scans revenue regulatory cleared 540 global sites 344k across FY26 FY26 $7.1m Cash at 30 June 2026 Regulatory & U.S.
Slide 12: Share price performance since July 2025
Share price performance since 1 July 2025 Strong share price performance, including relative to ASX listed med-tech industry peers rsonal use only 3,000% FY26 YTD FY27 4DX 2,000% 1,712% AYA CYC 4DMedical EIQ ENL M7T NAN U.S. Academic Medical CT:VQ® markets PCK 1,000% Centres early adaptors PME of CT
Slide 13: Product portfolio: a complete lung health solution
Regulatory & reimbursement 4DMedical’s product portfolio: a complete lung health solution A market-leading portfolio of pulmonary structure, function and cardiovascular imaging products rsonal use only delivered via a powerful, scalable SaaS platform CMS Category Product FDA reimbursement CE Mark TG
Slide 14: CT:VQ FDA clearance, CMS reimbursement
Regulatory & reimbursement CT:VQ® FDA clearance, CMS reimbursement Transformational milestone: CT:VQ® FDA clearance rsonal use only CT:VQ® becomes the world’s first and only non-contrast, CT-based ventilation-perfusion imaging technology to receive FDA clearance Reimbursement for CT:VQ® from the
Slide 15: U.S. commercial adoption: CT:VQ early adopters
U.S. commercial adoption CT:VQ® early adopters rsonal use only Strategy for adoption at top-tier, influential, U.S. CT:VQ® enters U.S. Outpatient Market academic medical centres and health systems via SimonMed agreement Top 20 U.S. Hospitals Top 20 – U.S. Hospitals * Interventional Pulmonology 1 • T
Slide 16: Philips and Veterans Affairs opportunity
U.S. commercial adoption Philips and Veterans Affairs opportunity Combined capabilities to build a compelling offer for ‘owning the lung’ and shared purpose rsonal use only Veterans Affairs (VA) opportunity Philips opportunity Why does VA need to act? • The U.S. PACT Act has appropriated • 4DMedical
Slide 17: CLEAR: expansion into acute pulmonary embolism market
Evidence & market expansion CLEAR: expansion into acute pulmonary embolism market rsonal use only • 4DMedical has launched CLEAR (Contrast-free Lung Nuclear VQ Evaluation for Acute Risk in pulmonary embolism) 1 million scans per year CT Pulmonary Solving supply side limitations • CLEAR’s core study
Slide 18: Clinical Validation
Evidence & market expansion Clinical Validation rsonal use only Major publication validates CT:VQ® for lung surgery Major independent multicentre trial involving U.S. veterans validates the use of 4DMedical’s imaging • Published in the American Journal of Respiratory and Critical Care Medicine, the
Slide 19: Commercial progress: Australia
Australian commercial adoption Commercial progress: Australia rsonal use only TGA regulatory clearance for CT:VQ® and immediate deployments via key radiology clinics CT:VQ® cleared by the Therapeutic Goods Administration (TGA) and listed in the Australian Register of Therapeutic Goods (ARTG) Comme
Slide 20: European expansion: Acquisition of contextflow
European commercial progress European expansion rsonal use only Acquisition of contextflow Immediate European presence in one of the world’s largest healthcare markets, with demand for advanced lung diagnostics supported by ageing populations, a high and rising burden of respiratory disease, and e
Slide 21: Enhancing patient journey: key partnerships and investments
Global patient platform Enhancing patient journey: key partnerships and investments Lung Cancer screening: Find, Understand, Act rsonal use only SCREEN contextflow DeteCT Finds and NAVIGATE QUALIFY PLAN TREAT MONITOR Quantifies Lung Nodules INTERVENTIONAL PULMONOLOGY/ SURGEON Routes CT:VQ® LDAi+ CAC
Slide 22: FY27 commercialisation priorities
FY27 commercialisation priorities rsonal use only • Commercial contracts • CT:VQ® penetration • Continued CT:VQ® • CLEAR study focusing with Philips VA sites across existing adoption across on pulmonary • Deployment-related contextflow sites Radiology Networks embolism imaging – respiratory disease
Slide 23: Procedural matters
Procedural matters rsonal use only 20
Slide 24: Formal Business
Formal Business rsonal use only 21
Slide 25: Items of Business
Items of Business Item 1: Financial Report, Directors’ Report and Auditors Report rsonal use only Item 2: Remuneration Report Item 3: Re-election of Director, Dr Geraldine McGinty Item 4: Proposed issue of Equity Securities to Non-Executive Directors Item 5: Issue of RSUs and Options to the Managing
Slide 26: Item 1: Financial Report, Directors' Report and Auditors Report
Formal Business rsonal use only Item 1: Financial Report, Directors’ Report and Auditors Report To receive and consider the Financial Report of the Company and its controlled entities and the Reports of the Directors and Auditor for the year ended 30 June 2026. 23 4DMedical Limited (ASX:4DX) October
Slide 27: Item 2: Remuneration report
Formal Business rsonal use only Item 2: Remuneration report To consider, and if thought fit, to pass, the following as an ordinary resolution: “That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2026, is adopted.” In Favour Against Proxy Discretion Abs
Slide 28: Item 3: Re-election of Dr Geraldine McGinty
Formal Business rsonal use only Item 3: Re-election of Dr Geraldine McGinty To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of clause 13.3(b) of the Constitution, Listing Rule 14.4, and for all other purposes, Dr Geraldine McGinty, a non- ex
Slide 29: Items 4A to 4C: Issue of Equity Securities to Directors
Formal Business Items 4A to 4C: Proposed issue of Equity Securities to Directors rsonal use only Item 4A In Favour Against Proxy Abstain To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rule 10.14 and for all other purposes, Sh
Slide 30: Item 5: Issue of RSUs and Options to the MD and CEO
Formal Business rsonal use only Item 5: Issue of RSUs and Options to the Managing Director and CEO To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purpos
Slide 31: Item 6: Issue of Options to the Executive Director and CFO
Formal Business rsonal use only Item 6: Issue of Options to the Executive Director and CFO To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes, Shar
Slide 32: Item 7: Renewal of approval for the Incentive Plan
Formal Business rsonal use only Item 7: Renewal of approval for the Incentive Plan To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rules 7.1 and 7.2 Exception 13 and for all other purposes, the 4DMedical Long Term Incentive Plan (
Slide 33: Item 8: Issue of the contextflow Options
Formal Business rsonal use only Item 8: Approval for the proposed issue of the contextflow Options To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve the proposed issue of up
Slide 34: Item 9: Ratification of prior issue of shares
Formal Business rsonal use only Item 9: Ratification of prior issue of shares To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the prior issue of 34,907,388 Shares on the ter
Slide 35: Item 10: Non-Executive Directors' Fee
Formal Business rsonal use only Item 10: Non-Executive Directors’ Fee To consider, and if thought fit, to pass, the following as an ordinary resolution: “That for the purposes of clause 13.4 of the Company's constitution, ASX Listing Rule 10.17 and for all other purposes, the maximum aggregate direc
Slide 36: Item 11: Amendment to Constitution
Formal Business rsonal use only Item 11: Amendment to Constitution To consider, and if thought fit, to pass, the following as a special resolution: That, for the purposes of section 136(2) of the Corporations Act 2001 (Cth) and for all other purposes, the Members of the Company approve the amendment
Slide 37: Item 12: Election of Director, Prof Christine Jenkins
Formal Business rsonal use only Item 12: Election of Director, Prof Christine Jenkins To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of clause 13.1 of the Company's constitution, ASX Listing Rule 14.4, and for all other purposes, Prof Chris
Slide 38: Poll
rsonal use only Poll 35
Slide 39: rsonal use only
< ee) o& A\uo asn yeuosse
Slide 40: 4DMedical Limited (ASX:4DX) Annual General Meeting October 2026
rsonal use only 4DMedical Limited (ASX:4DX) Annual General Meeting 28 October 2026 Copyright © 4DMedical Limited 2026 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia www.4dmedical.com ABN 31 161 684 831 37